Cepheid Gets CE Mark for Drug-Resistant Bacteria Dx; Partners with Pharma for US Development
This article has been updated from a previous version to include information about Cepheid's pharmaceutical partnerships around the Xpert Carba-R assay.
Cepheid Partners with AstraZeneca, GSK, Cubist to Develop Rapid Dx for Drug-Resistant Pathogens
NEW YORK (GenomeWeb) – Cepheid is collaborating with AstraZeneca, Cubist Pharmaceuticals, and GlaxoSmithKline to develop a rapid diagnostic test that can analyze multi-drug resistant pathogens and help doctors prescribe the most beneficial antibiotics for patients.
Alnylam Pharmaceuticals this week provided an update to its research and development activities, adding a new preclinical program to its pipeline with ALN-AS1 for acute intermittent porphyria while dropping its refractory anemia drug ALN-HPN in order to focus on “higher priority”
In another setback to its respiratory syncytial virus program, Alnylam Pharmaceuticals announced this week that its RSV therapeutic candidate ALN-RSV01 failed to meet the primary endpoint in a phase IIb trial.
The company also disclosed that it and partner Cubist Pharmaceuticals have decided to put on hold the development of a second-generation version of Alnylam's respiratory syncytial virus treatment, although no details regarding the decision were provided.
Dec 9, 2010
Jul 23, 2009